Masimo Stock

Masimo FCF/Debt

Delisted·Jun 12, 2026

The Free Cash Flow to Debt Ratio of Masimo (MASI) as of Aug 7, 2026 is 19.75 %. In the previous year, Free Cash Flow to Debt Ratio was 9.23 % — a change of 113.92% (higher).

FCF/Debt

19.75 %

YoY

113.92%

Last updated:

Free Cash Flow to Debt Ratio of Masimo is 2026 19.75 % . Free Cash Flow to Debt Ratio of Masimo was 2025 9.23 % . It decreases by 113.92% higher compared to the previous year.
Access this data via the Eulerpool API

Masimo Stock analysis

What does Masimo do? Masimo Corporation is an American medical technology company based in Irvine, California. The company was founded in 1989 by Professor Joe Kiani, who is still the chairman and CEO of the company today. With innovative products and advanced technology, Masimo aims to optimize medical diagnostic and treatment procedures to improve patient care. The business model of Masimo Corp focuses on developing and marketing products and solutions for patient monitoring and treatment in hospitals, intensive care facilities, and outpatient clinics. The company relies on high levels of innovation and collaboration with physicians, scientists, and other experts. The goal is to improve existing medical procedures, explore new applications for the technology, and optimize patient care. Masimo Corp's products are divided into different divisions that focus on various aspects of medical care. One example is the "Patient Monitoring" division, which offers various monitoring systems for vital signs such as respiration, pulse, and oxygen saturation. This includes products like the Rad-67 pulse oximeter or the Root patient monitor, which continuously monitor patients during treatment to enhance safety and effectiveness. Another division is "Anesthesia and Sedation," which focuses on solutions for anesthesiologists and intensive care specialists. Masimo Corp offers products such as the SedLine brain monitor or the EMMA main gas monitor, which enable physicians to control anesthesia depth more precisely and reduce the risk of complications. In addition to patient monitoring systems, Masimo Corp also provides solutions for neonatal care. The "Neonatal Care" division includes products like the Masimo Radical-7 pulse oximeter for monitoring premature infants or the Pronto-7 pulse oximeter for fast and accurate monitoring of newborns in the delivery room. Furthermore, Masimo Corp has developed products for monitoring surgical patients. The "Surgical and Minimally Invasive Monitoring" division, for example, offers the MOC-9 monitoring system for precise monitoring of hemodynamics during surgery. A unique product of Masimo Corp is also the Masimo SET sensor, which provides more accurate and reliable measurement of blood oxygen saturation than traditional pulse oximeter sensors. The company has filed over 100 patents worldwide for this technology and has been recognized with numerous awards and accolades. In summary, Masimo Corp is an innovative company specializing in improving medical care through the development and marketing of products for patient monitoring and treatment. With its state-of-the-art technologies and collaboration with experts in medical research, Masimo Corp sets standards for patient safety and treatment effectiveness. Masimo is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Masimo stock

Free Cash Flow to Debt Ratio of Masimo is 19.75 % in 2026.

Free Cash Flow to Debt Ratio of Masimo changed from 9.23 % to 19.75 %, representing a 113.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Masimo since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Masimo with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Masimo

All Key Metrics — Masimo